Clinical trials: Vascular Death
Chronic Kidney Disease, Cardiovascular Disease
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Trial name
- FAVORIT (NCT00064753)
- Testing
- High Dose Multivitamin, Low Dose Multivitamin
- Where
- 30 sites in United States, Brazil and 1 more
- Volunteers
- 4,110 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Reperfusion Injury, Liver Injury
Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation
This blinded, placebo-controlled study will administer inhaled nitric oxide to patients undergoing liver transplantation. The purpose of the study is to test if inhaled nitric oxide prevents liver injury associated with the…
- Trial name
- NCT00582010
- Testing
- inhaled nitric oxide, nitrogen gas
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
Moderate Risk of CVD
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk.
- Trial name
- ARRIVE (NCT00501059)
- Testing
- Aspirin (Acetylsalicylic acid, BAYE4465)
- Where
- 466 sites in United States, Germany and 6 more
- Volunteers
- 12,546 people
- Sponsor
- Bayer
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Pulmonary Embolism
Breath Analysis Technique to Diagnose Pulmonary Embolism
A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs, but it is not always accurate for individuals…
- Trial name
- NCT00368836
- Testing
- BreathScreen PE
- Where
- United States
- Volunteers
- 475 people
- Sponsor
- Wake Forest University Health Sciences
Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer.
- Trial name
- NCT03517449
- Testing
- Pembrolizumab, Lenvatinib, Paclitaxel
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 827 people
- Sponsor
- Eisai Inc.
Lactation Suppressed
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
This research study investigates the use of a drug, cabergoline, given immediately after second-trimester abortion or perinatal loss to decrease breast engorgement.
- Trial name
- LISTA (NCT04701333)
- Testing
- Cabergoline 1 MG
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Stanford University
Myocardial Infarction, Death
Relation Between NLR and IMR in STEMI Patients
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases.
- Trial name
- NCT02828137
- Volunteers
- 123 people
- Sponsor
- Inha University Hospital
Myocardiopathies, Ischemia, Myocardial
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
- Conditions
- Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac
- Trial name
- EMMA (NCT00376532)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Myocardial Infarction, Ventricular Dysfunction
Vest Prevention of Early Sudden Death Trial and VEST Registry
This study explores the hypothesis that wearable defibrillators can impact mortality by reducing sudden death during the first three months after a heart attack in persons with high risk for life-threatening arrhythmias.
- Conditions
- Myocardial Infarction, Ventricular Dysfunction, Sudden Death, Ventricular Tachycardia
- Trial name
- VEST (NCT01446965)
- Testing
- wearable defibrillator
- Where
- 71 sites in United States, Germany and 1 more
- Volunteers
- 2,348 people
- Sponsor
- University of California, San Francisco
Ischemic Stroke
China Antihypertensive Trial in Acute Ischemic Stroke
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.
- Trial name
- CATIS (NCT01840072)
- Testing
- Active antihypertensive treatment
- Where
- China
- Volunteers
- 4,071 people
- Sponsor
- Tulane University
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction, Death, Sudden, Cardiac
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack.
- Trial name
- OmegaREMODEL (NCT00729430)
- Testing
- Omega-3 Fatty Acids (Fish Oil Supplements)
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Brigham and Women's Hospital
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca